Cabaletta Bio, Inc.
No enriched coverage for $CABA in the last 7 days.
No SEC Form 4 filings for $CABA in the last 30 days.
This report indicates that Cabaletta Bio has filed a Form 8-K which is a current report used to announce events that shareholders should know about. Without further details, the specific nature of the event cannot be determined. Investors should review the full filing for more information.
Cabaletta Bio Inc.'s stock surged by roughly 32% after reporting early positive results from a small cell-therapy trial and announcing a $150 million stock sale that included Eli Lilly as an investor. The company's new funds, combined with existing cash, are expected to cover operating and capital needs into mid-2027. Cabaletta is also preparing to present fresh data from its rese-cel trial at the American Society of Gene & Cell Therapy meeting on May 14.
Cellares announced that the first two patients have been dosed with Cabaletta Bio's investigational CAR T cell therapy, rese-cel, manufactured using Cellares' automated Cell Shuttle platform. This milestone demonstrates the feasibility of scalable, automated manufacturing for autologous cell therapies, aiming for high capacity, flexible supply, and reduced costs. Cabaletta Bio's CEO, Steven Nichtberger, highlighted this a significant achievement towards minimizing capital investment and lowering the cost of goods for their therapeutic programs.
